Skip to content
The Policy VaultThe Policy Vault

Alecensa (alectinib capsules – Genentech)Cigna

Non-Small Cell Lung Cancer – Advanced or Metastatic Disease

Initial criteria

  • Patient age ≥ 18 years
  • Patient has anaplastic lymphoma kinase (ALK)-positive disease
  • The mutation was detected by an approved test

Approval duration

1 year